FDA Approves Bylvay for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

PARIS, FRANCE, 13 June 2023– Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has approved Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news